Use of monoclonal antibody immunosuppressive therapy in pediatric renal and liver transplantation

Publisher Website
Google Scholar
Abstract
OKT3, a murine monoclonal antibody directed against the human CD3 antigen, has proven effective in treating and preventing acute rejection in pediatric transplant recipients. Rejection reversal rates have ranged from 68‐93% in children receiving kidney transplants and 80‐93% in children receiving liver transplants. Single prophylactic studies with OKT3 in pediatric renal and liver transplants have reported outstanding 87% and 86% 1‐year graft survivals, respectively. Immunological monitoring of OKT3 therapy is essential to determine dosing changes and the ability to re‐use the monoclonal antibody.